WHO ICTRP trial
Phase II Clinical Study of Imiquimod Cream Combined with Aipalolitovorelizumab…
ChiCTR2500112788 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2500112788 |
|---|---|
| Public title | Phase II Clinical Study of Imiquimod Cream Combined with Aipalolitovorelizumab Plus Albumin-Bound Paclitaxel/Carboplatin in the Neoadjuvant Treatment of Early-Stage High-Risk Triple-Negative Breast Cancer |
| Scientific title | Phase II Clinical Study of Imiquimod Cream Combined with Aipalolitovorelizumab Plus Albumin-Bound Paclitaxel/Carboplatin in the Neoadjuvant Treatment of Early-Stage High-Risk Triple-Negative Breast Cancer |
| Primary sponsor | The first affiliated hostipal of nanchang university |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 2 |
| Countries | China |
| Conditions | Breast cancer |
| Interventions | Treatment group:Topical Imiquimod Cream Combined with Aipalolitovorelizumab Plus Chemotherapy |
| Registration date | Nov 19, 2025 |
| Target size | Treatment group:45 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: